CN115768879A - 用于培养细胞的方法 - Google Patents

用于培养细胞的方法 Download PDF

Info

Publication number
CN115768879A
CN115768879A CN202180044405.3A CN202180044405A CN115768879A CN 115768879 A CN115768879 A CN 115768879A CN 202180044405 A CN202180044405 A CN 202180044405A CN 115768879 A CN115768879 A CN 115768879A
Authority
CN
China
Prior art keywords
aspects
concentration
potassium ions
medium
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180044405.3A
Other languages
English (en)
Chinese (zh)
Inventor
S·K·沃德纳拉
R·L·艾尔
N·P·莱斯提弗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lyle Immune Pharmaceutical Co ltd
Original Assignee
Lyle Immune Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyle Immune Pharmaceutical Co ltd filed Critical Lyle Immune Pharmaceutical Co ltd
Publication of CN115768879A publication Critical patent/CN115768879A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4234—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Virology (AREA)
CN202180044405.3A 2020-04-28 2021-04-28 用于培养细胞的方法 Pending CN115768879A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063016907P 2020-04-28 2020-04-28
US63/016,907 2020-04-28
PCT/US2021/029762 WO2021222479A1 (en) 2020-04-28 2021-04-28 Methods for culturing cells

Publications (1)

Publication Number Publication Date
CN115768879A true CN115768879A (zh) 2023-03-07

Family

ID=75954306

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180044405.3A Pending CN115768879A (zh) 2020-04-28 2021-04-28 用于培养细胞的方法

Country Status (11)

Country Link
US (2) US12365871B2 (https=)
EP (1) EP4143300A1 (https=)
JP (1) JP2023524047A (https=)
KR (1) KR20230017786A (https=)
CN (1) CN115768879A (https=)
AU (1) AU2021265797A1 (https=)
BR (1) BR112022021551A2 (https=)
CA (1) CA3158133A1 (https=)
IL (1) IL297751A (https=)
MX (1) MX2022013599A (https=)
WO (1) WO2021222479A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021189008A1 (en) 2020-03-20 2021-09-23 Lyell Immunopharma, Inc. Novel recombinant cell surface markers
CA3158133A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
AU2022378579A1 (en) * 2021-10-28 2024-05-02 Lyell Immunopharma, Inc. Methods of generating cells
WO2023076577A2 (en) * 2021-10-28 2023-05-04 Memorial Sloan-Kettering Cancer Center Methods for modulating cell pluripotency and self-renewal property
JP2025508482A (ja) 2022-02-25 2025-03-26 カンステム バイオテック カンパニー リミテッド 無血清培地を用いた幹細胞の培養方法
WO2023163560A1 (ko) 2022-02-25 2023-08-31 주식회사 강스템바이오텍 마이크로캐리어를 이용한 줄기세포 배양 방법
CN114958737B (zh) * 2022-03-28 2024-02-09 苏州系统医学研究所 一种干性记忆t细胞的体外扩增方法及其应用
IT202200010535A1 (it) 2022-05-20 2023-11-20 Humanitas Mirasole Spa Cellule t cd8+ potenziate per l'immunoterapia del cancro
WO2025235403A1 (en) * 2024-05-06 2025-11-13 Vertex Pharmaceuticals Incorporated Differentiation of pancreatic islet cells

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110520438A (zh) * 2017-02-03 2019-11-29 匹兹堡大学联邦系统高等教育 溶瘤病毒疗法
US20210071141A1 (en) * 2018-04-24 2021-03-11 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof
CN117083376A (zh) * 2021-02-25 2023-11-17 莱尔免疫制药公司 用于培养细胞的方法
CN118308300A (zh) * 2024-04-16 2024-07-09 苏州纽博立科技有限公司 一种用于t细胞体外培养的细胞培养基及其制备方法和应用
CN118451098A (zh) * 2021-10-28 2024-08-06 莱尔免疫制药公司 培养表达c-jun的细胞的方法
CN118829725A (zh) * 2021-10-28 2024-10-22 莱尔免疫制药公司 生成细胞的方法

Family Cites Families (198)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86278A (en) 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
WO1990010059A1 (en) 1989-02-21 1990-09-07 Terumo Corporation A process for the generation of proliferating cd4 lymphocytes
WO1990014097A1 (en) 1989-05-15 1990-11-29 E.I. Du Pont De Nemours And Company Improved culture of human tumor-infiltrating lymphocytes by combining gas permeable bags and a primary culture container
IT1261180B (it) 1993-02-10 1996-05-09 Metodo di propagazione in vitro di cellule til.
AU7169296A (en) 1995-09-27 1997-04-17 Board Of Trustees Of The Leland Stanford Junior University Methods for determining t-cell profiles of immunocompromised subjects
DE69713336T2 (de) 1996-03-30 2002-12-05 Science Park Raf S.P.A., Milano Verfahren zur Herstellung von aktivierten markierten tumorspezifischen T-Zellen und deren Verwendung in der Behandlung von Tumoren
US20020081635A1 (en) 2000-05-11 2002-06-27 Thomas Terry E. Novel antibody compositions for preparing enriched T cell preparations
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
ES2629395T3 (es) 2001-10-04 2017-08-09 Genetics Institute, Llc Métodos y composiciones para modular la actividad de la interleucina-21
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
AU2002353822B2 (en) 2002-10-15 2008-11-06 The Government Of The United States Of America Represented By The Secretary Department Of Health And Human Services Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer
US7381405B2 (en) 2002-10-15 2008-06-03 The United States Of America As Represented By The Department Of Health And Human Services Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer
US20050249712A1 (en) 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
EP1814580B1 (en) 2004-11-24 2016-08-10 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
WO2007063424A2 (en) 2005-06-09 2007-06-07 Gal Markel The modulation of immunity and ceacam1 activity
JP5156382B2 (ja) 2005-09-30 2013-03-06 タカラバイオ株式会社 Ｔ細胞集団の製造方法
JPWO2007037544A1 (ja) 2005-09-30 2009-04-16 国立大学法人京都大学 制御性ｔ細胞の製造を向上させる薬剤のスクリーニング方法の開発、及び免疫抑制性のマクロライド系抗生剤を用いる制御性ｔ細胞の製造方法
AU2006328945B2 (en) 2005-12-21 2011-06-30 Sentoclone International Ab Method for treating malignant melanoma
US8007785B2 (en) 2005-12-21 2011-08-30 Sentoclone International Ab Method for treating colon cancer with tumour-reactive T-lymphocytes
WO2008033403A2 (en) 2006-09-13 2008-03-20 The Trustees Of Columbia University In The City Of New York Agents and methods to elicit anti-tumor immune response
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
AU2007331672A1 (en) 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
FR2911346B1 (fr) 2007-01-12 2012-12-07 Ct Hospitalier Universitaire De Nantes Procede de culture in vitro de lymphocytes t,en particulier de lymphocytes t infiltrant les tumeurs dits til
US20100136597A1 (en) 2007-04-26 2010-06-03 Nathalie Demotte Method for modularting activity of t lymphocytes
BRPI0915255A2 (pt) 2008-11-13 2018-02-06 Inst De Medicina Molecular célula t assassina natural foxp3+; população de células; e método para produção e aumento do número de células t assassinas naturais foxp3+; método para administrar uma célula t assassinanatural ao fígado ou ao tecido da mucosa em um indivíduo, e para suprimir uma resposta imunológica em órgão de um indivíduo, e composição farmacêutica
WO2010065959A1 (en) 2008-12-05 2010-06-10 Northeastern University Method of preparing adenosine-resistant anti-tumor t lymphocytes for adoptive immunotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
US9512401B2 (en) 2010-10-01 2016-12-06 Board Of Regents, The University Of Texas System B and T lymphocyte attenuator marker for use in adoptive T-cell therapy
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
RU2011130448A (ru) 2011-07-22 2013-01-27 Зао "Евроген" Методы и наборы для увеличения разнообразия т-клеток
CN103906516A (zh) 2011-09-21 2014-07-02 干细胞医药有限公司 用于增强T细胞介导的免疫应答的β-内酰胺化合物
PL2768939T3 (pl) 2011-10-21 2017-02-28 Cell Medica Limited Urządzenie do aseptycznego rozwoju komórek
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
WO2013134464A1 (en) 2012-03-07 2013-09-12 Children's Medical Center Corporation Tissue constructs and uses thereof
WO2013167136A1 (en) 2012-05-08 2013-11-14 Herlev Hospital Improving adoptive cell therapy with interferon gamma
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
US10316289B2 (en) 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
US20150017120A1 (en) 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
US10233425B2 (en) 2013-09-16 2019-03-19 The Trustees Of The University Of Pennsylvania CD137 enrichment for efficient tumor infiltrating lymphocyte selection
US9886736B2 (en) 2014-01-20 2018-02-06 Nvidia Corporation Selectively killing trapped multi-process service clients sharing the same hardware context
WO2015112626A1 (en) 2014-01-21 2015-07-30 June Carl H Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
WO2015127190A1 (en) 2014-02-21 2015-08-27 Argos Therapeutics, Inc. Tscm cells and methods for use
AU2015231041B2 (en) 2014-03-20 2020-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tumor-infiltrating lymphocytes for adoptive cell therapy
WO2015154065A1 (en) 2014-04-05 2015-10-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase 6 inhibition for enhancing t-cell function during anti-tumor response and tumor-peptide vaccination
WO2015157636A1 (en) 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
AU2015273531B2 (en) 2014-06-10 2021-07-29 Polybiocept Gmbh Culture medium for cellular immunotherapy
RU2739770C2 (ru) 2014-06-11 2020-12-28 полибайосепт ГмбХ Экспансия лимфоцитов с использованием композиции цитокинов для активной клеточной иммунотерапии
WO2015188839A2 (en) 2014-06-13 2015-12-17 Immudex Aps General detection and isolation of specific cells by binding of labeled molecules
DK4074735T3 (da) * 2014-08-28 2025-07-14 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
CA3017170C (en) 2014-09-17 2021-03-23 The Johns Hopkins University Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
BR112017005631A2 (pt) 2014-09-19 2018-06-26 City Of Hope células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2
AU2014407539B2 (en) 2014-10-02 2020-10-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation
IL297773B2 (en) 2014-11-17 2024-07-01 Adicet Bio Inc Engineered gamma delta t-cells
US10815457B2 (en) 2014-11-24 2020-10-27 University Of Pittsburgh Of The Commonwealth Systems Of Higher Education Active CXCR4+ immune cells and methods for their production and use
AU2015358334A1 (en) 2014-12-05 2017-06-08 Dana-Farber Cancer Institute, Inc. Bromodomain inhibitor as adjuvant in cancer immunotherapy
EP3034092A1 (en) 2014-12-17 2016-06-22 Université de Lausanne Adoptive immunotherapy for treating cancer
AU2016249005B2 (en) 2015-04-17 2022-06-16 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
CN117467603A (zh) 2015-04-27 2024-01-30 癌症研究技术有限公司 治疗癌症的方法
FR3040396A1 (fr) 2015-06-30 2017-03-03 Chu Nantes Procede de cryoconservation de lymphocytes infiltrant la tumeur
CA2992989A1 (en) 2015-07-21 2017-01-26 City Of Hope T cells for expression of chimeric antigen receptors and other receptors
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
KR20180063320A (ko) 2015-10-20 2018-06-11 카이트 파마 인코포레이티드 T 세포 요법을 위한 t 세포를 제조하는 방법
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
WO2017087784A1 (en) 2015-11-18 2017-05-26 Duke University Tumor infiltrating lymphocytes for treatment of cancer
RU2018127657A (ru) 2015-12-30 2020-01-31 Новартис Аг Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью
WO2017117521A1 (en) 2015-12-31 2017-07-06 Berkeley Lights, Inc. Tumor infilitrating cells engineered to express a pro-inflammatory polypeptide
EP3403099A4 (en) 2016-01-15 2019-09-04 The Wistar Institute Of Anatomy And Biology METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
SG11201805186VA (en) 2016-01-20 2018-07-30 Fate Therapeutics Inc Compositions and methods for immune cell modulation in adoptive immunotherapies
GB201601868D0 (en) 2016-02-02 2016-03-16 Lytix Biopharma As Methods
US20180135011A1 (en) 2017-03-13 2018-05-17 Berkeley Lights, Inc. Selection and cloning of t lymphocytes in a microfluidic device
GB201608060D0 (en) 2016-05-09 2016-06-22 Univ Birmingham Method of culturing T cells
WO2017210677A1 (en) 2016-06-03 2017-12-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education USE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA (PGC1α) AGONISTS TO IMPROVE EX VIVO EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS)
SG11201811408PA (en) 2016-06-24 2019-01-30 Univ Mcmaster Adoptive cell transfer and oncolytic virus combination therapy
MA45595A (fr) 2016-07-07 2019-05-15 Iovance Biotherapeutics Inc Protéines de liaison au ligand (1) de mort programmée (1) (pd-l1) et leurs procédés d'utilisation
EP3500298A4 (en) 2016-08-17 2020-04-01 University Health Network REGULATION OF TUMOR ASSOCIATED T CELLS
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
AU2017330379B2 (en) 2016-09-23 2023-07-13 Memorial Sloan Kettering Cancer Center Generation and use in adoptive immunotherapy of stem cell-like memory T cells
CA3036926C (en) 2016-09-30 2022-05-31 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
JP2019532953A (ja) 2016-09-30 2019-11-14 ノバルティス アーゲー 増強された有効性を有する免疫エフェクター細胞治療
CN110520530A (zh) 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
WO2018072105A1 (zh) 2016-10-19 2018-04-26 中山大学 一种干细胞样记忆性t细胞体外诱导剂及方法
HUE066460T2 (hu) 2016-10-26 2024-08-28 Iovance Biotherapeutics Inc A kriokonzervált tumor infiltráló limfociták restimulációja
AU2017347854B2 (en) 2016-10-27 2022-12-08 Intima Bioscience, Inc. Viral methods of T cell therapy
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US20190262400A1 (en) 2016-10-31 2019-08-29 H. Lee Moffitt Cancer Center And Research Institure, Inc. Artificial antigen presenting cells for expanding immune cells for immunotherapy
KR102618948B1 (ko) 2016-11-17 2023-12-27 이오반스 바이오테라퓨틱스, 인크. 잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법
US20200095547A1 (en) 2016-12-02 2020-03-26 Darya ALIZADEH Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
EP3548049A4 (en) 2016-12-05 2020-07-22 Fate Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
MX2019007963A (es) 2017-01-06 2019-10-21 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes de tumor (til) con agonistas de la superfamilia de recptor de factor de necrosis tumoral (tnfrsf) y combinaciones terapeuticas de til- y agonistas de tnfrsf.
US11157880B2 (en) 2017-01-09 2021-10-26 International Business Machines Corporation Enforcement of services agreement and management of emotional state
CN106834228B (zh) 2017-01-17 2021-03-23 上海新长安生物科技有限公司 一种体外扩增cd8+t细胞及其细胞亚群的方法
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
WO2018183930A1 (en) 2017-03-30 2018-10-04 Carson Dennis A Methods for isolating, expanding and administering cancer specific cd8+ t cells
US20200101108A1 (en) 2017-03-31 2020-04-02 The Board Of Trustees Of The Le-Land Standford Junior University Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
SG11201909087PA (en) 2017-03-31 2019-10-30 Boehringer Ingelheim Int Perfusion medium
GB201705504D0 (en) 2017-04-05 2017-05-17 Adaptimmune Ltd Methods of isolating naïve regulatory T cells
JP7538601B2 (ja) 2017-04-26 2024-08-22 ユーリカ セラピューティックス， インコーポレイテッド キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用
US20200377855A1 (en) 2017-05-05 2020-12-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rapid method for the culture of tumor infiltrating lymphocytes
KR20200003913A (ko) 2017-05-10 2020-01-10 이오반스 바이오테라퓨틱스, 인크. 액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
EP3622092A4 (en) 2017-05-11 2021-06-23 The Broad Institute, Inc. METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
AR112072A1 (es) 2017-06-05 2019-09-18 Iovance Biotherapeutics Inc Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
WO2019014684A1 (en) 2017-07-14 2019-01-17 Ohio State Innovation Foundation EXPANSION OF IMMUNE CELLS WITH INTERLEUKIN-INDUCIBLE T CELL KINASE-INHIBITING COMPOUNDS
JP2020528885A (ja) 2017-07-19 2020-10-01 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
EP3664835B1 (en) 2017-08-09 2024-10-23 Juno Therapeutics, Inc. Methods and compositions for preparing genetically engineered cells
WO2019040590A1 (en) 2017-08-22 2019-02-28 Translate Bio Ma, Inc. MODULATION OF THE EXPRESSION OF SOLUBLE FAS
WO2019036815A1 (en) 2017-08-24 2019-02-28 The Royal Institution For The Advancement Of Learning/Mcgill University ENHANCEMENT OF CD8 + T LYMPHOCYTES FOR ADOPTIVE CELL THERAPY BY INHIBITING PTPN1 (PTP1B) AND PTPN2 (TC-PTP))
BR112020005552A2 (pt) 2017-09-20 2020-10-27 Neximmune, Inc. composições de células compreendendo células t específicas de antígeno para terapia adotiva
US20210130776A1 (en) 2017-09-29 2021-05-06 The Broad Institute, Inc. Methods and compositions for modulating suppression of lymphocyte activity
US20200332251A1 (en) * 2017-10-13 2020-10-22 Boehringer Ingelheim International Gmbh Perfusion medium
WO2019077062A1 (en) 2017-10-18 2019-04-25 Vivia Biotech, S.L. C-CELLS ACTIVATED BY BIT
US20190127694A1 (en) 2017-10-27 2019-05-02 Augusta University Research Institute, Inc. Induced Stem Memory T-Cells and Methods of Use Thereof
EP3701041A4 (en) 2017-10-27 2021-11-17 The Trustees of The University of Pennsylvania METHODS AND COMPOSITIONS FOR TREATMENT OF DISEASES ASSOCIATED WITH EXHAUSTED T-CELLS
EP3707245A1 (en) 2017-11-06 2020-09-16 Ludwig Institute for Cancer Research Ltd Method for expansion of lymphocytes
SG11202004116QA (en) 2017-11-08 2020-06-29 Biontech Us Inc T cell manufacturing compositions and methods
CR20200251A (es) 2017-11-17 2020-07-17 Iovance Biotherapeutics Inc Expansión de til de aspirados con aguja fina y biopsias por punción
US20210369775A1 (en) 2017-12-15 2021-12-02 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
EP3737743A1 (en) 2018-01-08 2020-11-18 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
WO2019140137A1 (en) 2018-01-10 2019-07-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods of expansion of t cell populations
GB201801067D0 (en) 2018-01-23 2018-03-07 Price Nicola Kaye Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof
CA3090795A1 (en) 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
CA3094375A1 (en) 2018-03-28 2019-10-03 Board Of Regents, The University Of Texas System Use of histone modifiers to reprogram effector t cells
CA3094957A1 (en) 2018-03-29 2019-10-03 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2019201970A1 (en) 2018-04-19 2019-10-24 University Of Copenhagen A mertk ligand for adoptive t cell cancer therapy
WO2019210131A1 (en) 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
CA3100776A1 (en) 2018-05-18 2019-11-21 Children's National Medical Center System of cell expansion and methods of using the same
AU2019277271A1 (en) 2018-06-01 2020-12-03 Monash University Methods of activating cells via PTP 1B inhibition
US20210236547A1 (en) 2018-06-05 2021-08-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rapid production, expansion, and increased purity of car-t cells using beads with protein l
EP3801570A4 (en) 2018-06-05 2022-04-20 H. Lee Moffitt Cancer Center & Research Institute, Inc. ARTIFICIAL ANTIGEN PRESENTATION CELLS WITH PROTEIN L FOR EXPANSION OF IMMUNE CELLS FOR IMMUNOTHERAPY
WO2019241536A1 (en) 2018-06-14 2019-12-19 Lixte Biotechnology, Inc. Oxabicycloheptanes for enhancing car t cell function
US20210169937A1 (en) 2018-07-27 2021-06-10 Nordwest Polybiocept Bioscience Gmbh Method for the treatment of a tumor patient with adoptive t cell immunotherapy
AU2019314888A1 (en) 2018-07-31 2021-02-18 Polybiocept Gmbh Production and selection of tumor uber reactive immune cells (TURICs)
US20210299223A1 (en) 2018-07-31 2021-09-30 Washington University Use of interleukin-7 and chimeric antigen receptor (car)-bearing immune effector cells for treating tumor
EP3841196A4 (en) 2018-08-22 2022-09-21 Cellect Biotherapeutics Ltd. MODULATION OF CELLS RESPONSIVE TO APOPTOSIS
CA3110089A1 (en) 2018-08-28 2020-03-05 Fred Hutchinson Cancer Research Center Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
EP4635978A2 (en) 2018-08-31 2025-10-22 Novartis AG Methods of making chimeric antigen receptor-expressing cells
IL281423B2 (en) 2018-09-20 2024-08-01 Iovance Biotherapeutics Inc Expansion of TILS from cryopreserved tumor samples
CA3116406A1 (en) 2018-09-24 2020-04-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Culture of tumor infiltrating lymphocytes from tumor digest
JP7698577B2 (ja) 2018-10-18 2025-06-25 ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム 組織常在メモリー様ｔ細胞を生成するための方法及びその使用
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
WO2020092475A1 (en) 2018-10-31 2020-05-07 The Children's Hospital Of Philadelphia T cells from lymphatic fluid for diagnostic and therapeutic use
US20220002674A1 (en) 2018-10-31 2022-01-06 Bellicum Pharmaceuticals, Inc. T cells with suicide switch
JP7854297B2 (ja) 2018-11-05 2026-05-01 アイオバンス バイオセラピューティクス，インコーポレイテッド 改良された腫瘍反応性ｔ細胞の選択
MY210603A (en) 2018-11-05 2025-10-01 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2020096927A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
US12611427B2 (en) 2018-11-05 2026-04-28 Iovance Biotherapeutics, Inc. Treatment of NSCLC patients refractory for anti-PD-1 antibody
SG11202104611YA (en) 2018-11-08 2021-06-29 Neximmune Inc T cell compositions with improved phenotypic properties
CN113195710A (zh) 2018-12-06 2021-07-30 麒麟控股株式会社 T细胞或nk细胞的制造方法、t细胞或nk细胞的培养用培养基、t细胞或nk细胞的培养方法、维持未分化t细胞的未分化状态的方法和t细胞或nk细胞的增殖促进剂
CA3123392A1 (en) 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
WO2020146740A1 (en) 2019-01-10 2020-07-16 Iovance Biotherapeutics, Inc. System and methods for monitoring adoptive cell therapy clonality and persistence
KR20200092155A (ko) 2019-01-24 2020-08-03 울산대학교 산학협력단 종양침윤림프구를 유효성분으로 포함하는 삼중음성 유방암 예방 또는 치료용 조성물
EP3921419B1 (en) 2019-02-08 2026-04-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Sirt2-ablated chimeric t cells
WO2020180733A1 (en) 2019-03-01 2020-09-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
US20220177839A1 (en) 2019-03-05 2022-06-09 Shanghai Sinobay Biotechnology Co., Ltd. Composition, culture medium and method for inducing and/or amplifying tscm in vitro
CU24712B1 (es) 2019-03-15 2024-07-10 Centre Hospitalier Univ Vaudois Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva
JP7584437B2 (ja) 2019-04-05 2024-11-15 ２セブンティ バイオ インコーポレイテッド 抗ｂｃｍａ ｃａｒ ｔ細胞の製造
WO2020219812A1 (en) * 2019-04-26 2020-10-29 Allogene Therapeutics, Inc. Methods of manufacturing allogeneic car t cells
CN110157680A (zh) 2019-05-08 2019-08-23 浙江大学 提高嵌合抗原受体t细胞疗效和作用持久性的细胞培养方法
AR118859A1 (es) 2019-05-08 2021-11-03 Neon Therapeutics Inc Composiciones y métodos de fabricación de células t
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
KR102081585B1 (ko) 2019-05-16 2020-02-26 (주)녹십자셀 활성화 림프구 및 이의 제조 방법
EP3986427A1 (en) 2019-06-24 2022-04-27 Childrens Hospital Los Angeles Bcl11b overexpression to enhance human thymopoiesis and t cell function
WO2020263919A1 (en) 2019-06-24 2020-12-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. A peptide-based screening method to identify neoantigens for use with tumor infiltrating lymphocytes
WO2021011882A1 (en) 2019-07-17 2021-01-21 Case Western Reserve University Long lived t cells for treating hiv infection
GB201910605D0 (en) 2019-07-24 2019-09-04 Immetacyte Ltd Tumour infltracting lymphocyte therapy amd uses thereo
WO2021021804A1 (en) 2019-07-28 2021-02-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods, systems, and computer-readable media for predicting a cancer patient's response to immune-based or targeted therapy
US12558424B2 (en) 2019-08-07 2026-02-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cells having enhanced anti-tumor activity
WO2021034774A1 (en) 2019-08-16 2021-02-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CA3147441A1 (en) 2019-09-03 2021-03-11 Allogene Therapeutics, Inc. Methods of preparing t cells for t cell therapy
EP4034140A1 (en) 2019-09-24 2022-08-03 Nurix Therapeutics, Inc. Cbl inhibitors and compositions for use in adoptive cell therapy
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
EP4048295A1 (en) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP2023502780A (ja) 2019-11-25 2023-01-25 ケーエスキュー セラピューティクス， インコーポレイテッド 腫瘍浸潤リンパ球の活性化及び増殖方法
US20230032934A1 (en) 2019-11-27 2023-02-02 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
US12516291B2 (en) 2019-12-11 2026-01-06 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
MX2022007416A (es) 2019-12-18 2022-09-19 Cbio As Proceso mejorado para el cultivo de linfocitos infiltrantes de tumor para uso terapeutico.
BR112022011795A2 (pt) 2019-12-20 2022-08-30 Instil Bio Uk Ltd Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos
JP7793523B2 (ja) 2020-01-07 2026-01-05 アメリカ合衆国 人工多能性幹細胞を用いたｔ細胞集団の製造方法
CA3168337A1 (en) 2020-02-17 2021-08-26 Marie-Andree Forget Methods for expansion of tumor infiltrating lymphocytes and use thereof
KR20230034198A (ko) 2020-02-28 2023-03-09 케이에스큐 세러퓨틱스 인코포레이티드 종양 침윤 림프구의 활성화 및 확장 방법
CN111440773B (zh) 2020-04-07 2023-03-14 上海交通大学 一种t细胞体外嵌合抗原受体改造及扩增的优化培养方法
CA3158133A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
TW202237824A (zh) 2020-11-23 2022-10-01 美商萊爾免疫藥物股份有限公司 培養免疫細胞之方法
EP4298208A1 (en) 2021-02-25 2024-01-03 Lyell Immunopharma, Inc. Methods for culturing cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110520438A (zh) * 2017-02-03 2019-11-29 匹兹堡大学联邦系统高等教育 溶瘤病毒疗法
US20210071141A1 (en) * 2018-04-24 2021-03-11 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof
CN117083376A (zh) * 2021-02-25 2023-11-17 莱尔免疫制药公司 用于培养细胞的方法
CN118451098A (zh) * 2021-10-28 2024-08-06 莱尔免疫制药公司 培养表达c-jun的细胞的方法
CN118829725A (zh) * 2021-10-28 2024-10-22 莱尔免疫制药公司 生成细胞的方法
CN118308300A (zh) * 2024-04-16 2024-07-09 苏州纽博立科技有限公司 一种用于t细胞体外培养的细胞培养基及其制备方法和应用

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
EIL ROBERT等: "lonic immune suppression within the tumour microenvironment limits T cell effector function", NATURE, vol. 537, no. 7621, 14 September 2016 (2016-09-14), pages 539 - 543 *
FRANCESC BAIXAULI等: "Potassium shapes antitumor immunity", SCIENCE, vol. 363, no. 6434, 29 March 2019 (2019-03-29), pages 1395 - 1396 *
LUCA GATTINONI等: "A human memory T cell subset with stem cell - like properties", NATURE MEDICINE, vol. 17, no. 10, 18 September 2011 (2011-09-18), pages 1290 - 1297, XP055551014, DOI: 10.1038/nm.2446 *
LUCA GATTINONI等: "Paths to stemness: building the ultimate antitumour T cell", NATURE REVIEWS, vol. 12, no. 10, 21 September 2012 (2012-09-21), pages 671 - 684, XP055822942, DOI: 10.1038/nrc3322 *
VODNALA SK;: "钾离子是控制T细胞抗癌能力的关键所在", 生物医学工程与临床, no. 03, 25 May 2019 (2019-05-25), pages 102 *
VODNALA SUMAN KUMAR等: "T cell stemness and dysfunction in tumors are triggered by a common mechanism", SCIENCE, vol. 363, no. 6434, 29 March 2019 (2019-03-29), pages 1, XP093022249, DOI: 10.1126/science.aau0135 *
谢正栘、吴挹芳主编: "现代微生物培养基和试剂手册", vol. 1, 30 April 1994, 福建科学技术出版社, pages: 587 - 588 *

Also Published As

Publication number Publication date
WO2021222479A1 (en) 2021-11-04
US12365871B2 (en) 2025-07-22
BR112022021551A2 (pt) 2023-01-03
KR20230017786A (ko) 2023-02-06
US20210332326A1 (en) 2021-10-28
EP4143300A1 (en) 2023-03-08
US20260008999A1 (en) 2026-01-08
CA3158133A1 (en) 2021-11-04
IL297751A (en) 2022-12-01
MX2022013599A (es) 2023-01-24
JP2023524047A (ja) 2023-06-08
WO2021222479A9 (en) 2022-08-11
AU2021265797A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
CN115768879A (zh) 用于培养细胞的方法
US20240374728A1 (en) T Cell Modification
JP2021503959A (ja) がんおよび関連悪性腫瘍の治療のためのγδＴ細胞を活性化、修飾、および増殖させる方法
US20240228957A9 (en) Methods for culturing cells
JP2022542321A (ja) 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法
US20230181644A1 (en) Methods of generating cells
US20240216426A1 (en) Recombinant antigen presenting cells
TW202235094A (zh) 經回春的ｔ細胞之製造方法、包含彼之組成物、及彼之使用方法
CN117083376A (zh) 用于培养细胞的方法
JP2024517966A (ja) 同種異系ｃａｒ ｔ細胞療法のために幹細胞を操作すること
JP2024517968A (ja) 幹細胞からの操作されたｔ細胞の産生
US20250228939A1 (en) Enhanced immune cell therapy
WO2026006604A1 (en) Feeder cell replacement
WO2025217398A1 (en) Methods for culturing cells with improved culture medium
HK40117446A (en) T cell modification
WO2024071411A1 (ja) ｉＰＳ細胞から誘導された免疫細胞
WO2024077174A1 (en) Methods for culturing nr4a-deficient cells
TW202304481A (zh) 富含γδＴ細胞的新穎組合物，及其製備方法及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination